Skip to main content

Table 2 Summary of frequency of adverse events across the studies

From: Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

 

Placebo

AZD9164

 

GMAD, healthy subjects

n = 9

400 μg

1000 μg

2800 μg

Total (%)

  

n = 6

n = 6

n = 6

n = 27

Any AEa

8 (88.9)

5 (83.3)

6 (100)

6 (100)

25 (92.6)

SAEsa

1(11.1)

0 (0)

0 (0)

0 (0)

1 (3.7)

DAEsa

2 (22.2)

0 (0)

0 (0)

0 (0)

2 (7.4)

Total number of AEs

31

7

18

15

71

JMAD, healthy subjects

n = 6

400 μg

1000 μg

 

Total (%)

  

n = 6

n = 6

 

n = 18

Any AEa

3 (50.0)

6 (100.0)

4 (66.7)

 

13 (72.2)

SAEsa

0 (0)

0 (0)

0 (0)

 

0 (0)

DAEsa

0 (0)

0 (0)

0 (0)

 

0 (0)

Total number of AEs

3

10

7

 

20

GMAD, COPD patients

n = 1

 

n = 3

 

n = 4

Any AEa

1 (100)

 

3 (100)

 

4 (100)

SAEsa

0 (0)

 

0 (0)

 

0 (0)

DAEsa

0 (0)

 

1 (33.3)

 

1 (25.0)

Total number of AEs

1

 

8

 

9

  1. aNumber (%) of patients who had an AE in each category. Subjects with multiple events in the same category are counted only once in each category.